Why this matters: injectable GLP-1s like semaglutide and tirzepatide achieve 15 to 20% weight reductions, but injections, cost, and adherence limit real-world use (Santulli review, Journal of Diabetes & Metabolic Disorders, 2025)
To start GH replacement therapy, the diagnosis of patients with PWS without any confirmatory test is sufficient, while it is necessary to perform dynamic tests after the attainment of final height as the deficit is often not confirmed in adulthood [13]
The agency argues the changes are necessary because the 2024 rules imposed significant compliance costs on sterilization facilities and threatened supply chains for medical devices and pharmaceuticals
Higher concentrations naturally cost more, with typical options including 250mg, 500mg, and 1000mg doses
SOURCE: Wyyerd Fiber
Nature 387 , 206209 (1997)